Cytotoxic effects of sphingolipids as single or multi-modality agents on human melanoma and soft tissue sarcoma in vitro

Melanoma Research

Volumn 8, Issue 3, 1998, Pages 227-239

  Auzenne, E ^a   Leroux, M E ^a   Hu, M ^a   Pollock, R E ^a   Feig, B ^a   Klostergaard, J ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Apoptosis; ICE; Melanoma; Melphalan; Protein kinase C; Sarcoma; Sphingolipids; Tumour necrosis factor

Indexed keywords

N HEXANOYL DEXTRO SPHINGOSINE; PROTEIN KINASE C; SPHINGANINE; SPHINGOLIPID; SPHINGOSINE DERIVATIVE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG SENSITIVITY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LIMB PERFUSION; MELANOMA; MELANOMA CELL; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SOFT TISSUE SARCOMA;

ALKALOIDS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BENZOPHENANTHRIDINES; CARBOXYLIC ACIDS; CELL SURVIVAL; CERAMIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; FUMONISINS; HISTIOCYTOMA, BENIGN FIBROUS; HUMANS; LUNG NEOPLASMS; MELANOMA; MELPHALAN; PHENANTHRIDINES; PROTEIN KINASE C; SARCOMA; SIGNAL TRANSDUCTION; SPHINGOSINE; TIME FACTORS; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031864727     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-199806000-00005     Document Type: Article

References (60)

1. Lienard D, Ewalenko P, Delmotte J-J, et al. High-close recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992; 10: 52-60.
2. Lienard D, Lejeune FJ, Ewalenko P. In transit metastases of malignant melanoma treated by high dose rTNFα in combination with interferon-γ and melphalan in isolation perfusion. World Surg 1992; 16: 234-240.
3. Lienard D, Eggermont AMM, Schraffordt Koops H, et al. Isolated perfusion of the limb with high-dose tumour necrosis factor-alpha (TNF-α), interferon-gamma (IFN-γ) and melphalan for melanoma stage III. Results of a multi-centre pilot study. Melanoma Res 1994; 4: 21-26.
4. Fraker DL, Alexander HR. The use of tumour necrosis factor (TNF) in isolated perfusion: results and side effects. The NCI results. Melanoma Res 1994; 4: 27-29.
5. Vaglini M, Santinami M, Manzi R, et al. Treatment of in-transit metastases from cutaneous melanoma by isolation perfusion with tumour necrosis factor-alpha (TNF-α), melphalan and interferon-gamma (INF-γ). Dose-finding experience at the National Cancer Institute of Milan. Melanoma Res 1994; 4: 35-38.
6. Hill S, Thomas JM. Low-dose tumour necrosis factor-alpha (TNF-α) and melphalan in hyperthermic isolated limb perfusion. Results from a pilot study performed in the United Kingdom. Melanoma Res 1994; 4: 31-34.
7. Auzenne E, Feig B, Ross MI, et al. Tetramodality treatment of human melanoma in vitro. Melanoma Res 1995; 5: 49-57.
8. Jarvis D, Kolesnick R, Fornari F, et al. Induction of apoptotic DNA damage and cell death by activation of the sphingomyelin pathway. Proc Natl Acad Sci USA 1994; 91: 73-77.
9. Kolesnick R, Golde D. The sphingomyelin pathway in tumor necrosis factor and interleukin-1 signaling. Cell 1994; 77: 325-328.
10. Gulbins E, Bissonnette R, Mahboubi A, et al. FAS-induced apoptosis is mediated via a ceramide-initiated RAS signaling pathway. Immunity 1995; 2: 341-351.
11. Bose R, Verheij M, Haimovitz-Friedman A, et al. Ceramide synthase mediates daunorubicin-induced apoptosis: an alternative mechanism for generating death signals. Cell 1995; 82: 405-414.
12. Jaffrezou J-P, Levade T, Bettaieb A, et al. Daunorubicin-induced apoptosis: triggering of ceramide generation through sphingomyelin hydrolysis. EMBO J 1996; 15: 2417-2424.
13. Strum JC, Small GW, Pauig SB, et al. 1-β-D-arabinofur-anosylcytosine stimulates ceramide and diglyceride formation in HL-60 cells. J Biol Chem 1995; 269: 15493-15497.
14. Zhang J, Alter N, Reed JC, et al. Bcl-2 interrupts the ceramide-mediated pathway of cell death. Proc Natl Acad Sci USA 1996; 93: 5325-5328.
15. 3-induced HL-60 cell differentiation. J Biol Chem 1990; 265: 15823-15831.
16. Jayadev S, Liu N, Bielawska AE, Lee JY, et al. Role for ceramide in cell cycle arrest. J Biol Chem 1995; 270: 2047-2052.
17. Quintans J, Kilkus J, McShan CL, et al. Ceramide mediates the apoptotic response of WEHI-231 cells to anti-immunoglobulin, corticosteroids, and irradiation. Biochem Biophys Res Commun 1994; 202: 710-714.
18. Chang Y, Abe A, Shayman JA. Ceramide formation during heat shock: a potential mediator of αβ-crystallin transcription. Proc Natl Acad Sci USA 1995; 92: 12275-12279.
19. Haimovitz-Friedman A, Kan CC, Ehleiter D, et al. Ionizing radiation acts on cellular membranes in human leukemia cells to generate ceramide and induce apoptosis. J Exp Med 1994; 180: 525-535.
20. Hannun Y, Obeid L. Ceramide: an intracellular signal for apoptosis. Trends Biomed Sci 1995; 20: 73-77.
21. Jarvis WD, Grant S, Kolesnick RN. Ceramide and the induction of apoptosis. Clin Cancer Res 1996; 2: 1-6.
22. Wiegmann K, Schutze S, Machleidt T, et al. Functional dichotomy of neutral and acidic sphingomelinase in tumor necrosis factor signaling. Cell 1994; 78: 1005-1015.
23. Spiegel S, Merrill AH Jr. Sphingolipid metabolism and cell growth regulation. FASEB J 1996; 10: 1388-1397.
24. Liu J, Mathias S, Yang Z et al. Renaturation and TNFα stimulation of a 97 kDa ceramide-activated protein kinase. J Biol Chem 1994; 269: 3047-3052.
25. Yao B, Zhang Y, Delikat S, et al. Ceramide-activated protein kinase is a Raf kinase. Nature 1995; 378: 307-310.
26. Dobrowsky RT, Hannun YA. Ceramide stimulates a cytosolic protein phosphatase. J Biol Chem 1992; 267: 5048-5051.
27. Muller G, Ayoub M, Storz P, et al. PKCζ is a molecular switch in signal transduction of TNF-α, bifunctionally regulated by ceramide and arachidonic acid. EMBO J 1995; 14: 1961-1969.
28. Hannun YA, Bell RM. Functions of sphingolipids and sphingolipid breakdown products in cellular regulation. Science 1989; 243: 500-507.
29. Grant S, Jarvis WD. Modulation of drug-induced apoptosis by interruption of the protein kinase C signal transduction pathway: a new therapeutic strategy. Clin Cancer Res 1996; 2: 1915-1920.
30. Arnold RS, Newton AC. Inhibition of the insulin receptor tyrosine kinase by sphingosine. Biochemistry 1991; 30: 7747-7754.
31. Pushkareva MY, Khan WA, Alessenko AV, et al. Sphingosine activation of protein kinases in Jurkat T cells. In vitro phosphorylation of endogenous protein substrates and specificity of action. J Biol Chem 1992; 267: 15246-15251.
32. Kiss Z, Anderson WB. ATP stimulates the hydrolysis of phosphatidylethanolamine in NIH 3T3 cells. Potentiating effects of guanosine triphosphates and sphingosine. J Biol Chem 1990; 265: 7345-7350.
33. Bregman MD, Meyskens FL Jr. Difluoromethylornithine enhances inhibition of melanoma cell growth in soft agar by dexamethasone, clone A and retinoic acid. Int J Cancer 1986; 37: 101-107.
34. Lotan R. Different susceptibilities of human melanoma and breast carcinoma cell lines to retinoic acid-induced growth inhibition. Cancer Res 1979; 39: 1014-1019.
35. Hu M, Pollock RE, Nakamura T, et al. Human peritumoral and lung fibroblasts produce paracrine motility factors for recently established human sarcoma cell strains. Int J Cancer 1995; 62: 585-592.
36. Merrill AH, van Echten G, Wang E, et al. Fumonisin B1 inhibits sphingosine (sphinganine) N-acyl-transferase and de novo sphingolipid biosynthesis in cultured neurons in situ. J Biol Chem 1993; 268: 27299-27306.
37. Jarvis WD, Fornari FA, Traylor RS, et al. Induction of apoptosis and potentiation of ceramide-mediated cytotoxicity by sphingoid bases in human myeloid leukemia cells. J Biol Chem 1996; 271: 8275-8284.
38. Schwartz GK, Haimovitz-Friedman A, Dhupar SK, et al. Potentiation of apoptosis by treatment with the protein kinase C-specific inhibitor safingol in mitomycin C-treated gastric cancer cells. J Natl Cancer Inst 1995; 87: 1394-1399.
39. Basu A, Lazo JS. Sensitization of human cervical carcinoma cells to cis-diamminedichloroplatinum(II) by bryostatin 1. Cancer Res 1992; 52: 3119-3124.
40. Mohammed RM, Al-Katib A, Pettit GR, et al. Successful treatment of human Waldenstrom's macroglobulinemia with combination biological and chemotherapy agents. Cancer Res 1994; 54: 165-168.
41. Eggermont AM, Koops HS, Lienard D, et al. Isolated limb perfusion with high-dose tumor necrosis factor-α in combination with interferon-γ and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol 1996; 14: 2653-2665.
42. Eggermont AMM, Koops HS, Klausner JM, et al. Isolated limb perfusion with tumor necrosis factor and melphalan in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 1996; 224: 756-765.
43. Talmadge JE, Phillips H, Schneider M, et al. Immunomodulatory properties of recombinant murine and human tumor necrosis factor. Cancer Res 1988; 48: 544-550.
44. Manda T, Shimomura K, Mukumoto S, et al. Recombinant human tumor necrosis factor-α: evidence of an indirect mode of antitumor activity. Cancer Res 1987; 47: 3707-3711.
45. Watanabe N, Niitsu Y, Umeno H, et al. Toxic effect of tumor necrosis factor on tumor vasculature in mice. Cancer Res 1988; 48: 2179-2183.
46. Renard N, Lienard D, Lespangnard L, et al. Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumor necrosis factor alpha (rTNF alpha). Int J Cancer 1994; 57: 656-663.
47. Laster SM, Wood JG, Gooding LR. Tumor necrosis factor can induce both apoptotic and necrotic forms of cell lysis. J Immunol 1988; 141: 2629-2634.
48. Fraker DL, Alexander HR. Isolated limb perfusion with high-dose tumor necrosis factor for extremity melanoma and sarcoma. In: Devita VT, Hellman S, Rosenberg S, eds. Important Advances in Oncology. Philadelphia: J.B. Lippincott, 1994: 179-192.
49. Frank S, Hubner G, Brier G, et al. Regulation of vascular endothelial growth factor expression in cultured keratinocytes. Implications for normal and impaired wound healing. J Biol Chem 1995; 270: 12607-12613.
50. Posner MC, Lienard D, Lejeune FJ, et al. Hyperthermic isolated limb perfusion with tumor necrosis factor alone for melanoma. Cancer J 1995; 1: 274-280.
51. Schutze S, Potthoff K, Machleidt T, et al. TNF activates NF-κB by phosphatidylcholine-specific phospholipase C-induced 'acidic' sphingomyelin breakdown. Cell 1992; 71: 765-776.
52. Dbaibo GS, Obeid LM, Hannun YA. Tumor necrosis factor-α (TNF-α) signal transduction through ceramide. Dissociation of growth inhibitory effects of TNF-α from activation of nuclear factor-κB. J Biol Chem 1993; 268: 17762-17766.
53. Betts JC, Agranoff AB, Nabel GJ, et al. Dissociation of endogenovis cellular ceramide from NF-κB activation. J Biol Chem 1993; 269: 8455-8458.
54. Bezombes C, Maestre N, Laurent G, Levade T, et al. Restoration of TNF-α-induced ceramide generation and apoptosis in resistant human leukemia KG1a cells by the P-glycoprotein blocker PSC833. FASEB J 1998; 12: 101-109.
55. Jarvis WD, Fornari FA Jr, Browning JL, et al. Attenuation of ceramide-induced apoptosis by diglyceride in human myeloid leukemia cells. J Biol Chem 1994; 269: 31685-31692.
56. Chmura SJ, Nodenski E, Weichselbaum RR, et al. Protein kinase C inhibition induces apoptosis and ceramide production through activation of a neutral sphingomyelinase. Cancer Res 1996; 56: 2711-2714.
57. Endo K, Igarashi Y, Nisar M, et al. Cell membrane signaling as target in cancer therapy: inhibitory effect of N,N-dimethyl and N,N,N-trimethyl sphingosine derivatives in in vitro and in vivo growth of human tumor cells in nude mice. Cancer Res 1991; 51: 1613-1618.
58. Park YS, Hakamori S-I, Kawa S, et al. Liposomal N,N,N-trimethylsphingosone (TMS) as an inhibitor of B16 melanoma cell growth and metastasis with reduced toxicity and enhanced drug efficacy compared to free TMS: cell membrane signaling as a target in cancer therapy III. Cancer Res 1994; 54: 2213-2217.
59. Sweeney ELA, Sakakura C, Shirahama T, et al. Sphingo sine and its methylated derivative N,N-dimethylsphingosine (DMS) induce apoptosis in a variety of human canter cell lines. Int J Cancer 1996; 66: 358-366.
60. Schwartz GK, Ward D, Saltz L, et al. A pilot clinical/ pharmacological study of the protein kinase C-specific inhibitor safingol alone and in combination with doxorubicin. Clin Cancer Res 1997; 3: 537-544.